Molecular diagnosis of symptomatic toxoplasmosis: a 9-year retrospective and prospective study in a referral laboratory in São Paulo, Brazil

Lilian Muniz Camilo; Vera Lucia Pereira-Chioccola; Ricardo Gava; Cristina da Silva Meira-Strejevitch; Jose Ernesto Vidal; Cinara Cássia Brandão de Mattos; Fábio Batista Frederico; Luiz Carlos De Mattos; Lígia Cosentino Junqueira Franco Spegiorin; FAMERP Toxoplasma Research Group

doi:10.1016/j.bjid.2017.07.003

PMC full text:

Braz J Infect Dis. 2017 Nov-Dec; 21(6): 638–647.

Published online 2017 Sep 29. doi: 10.1016/j.bjid.2017.07.003

Copyright/LicenseRequest permission to reuse

Table 1

Summary of retrospective of qPCR analysis employing REP-529 and B1 primer sets in 515 DNA samples with results in clinical diagnosis, ELISA, and cPCR (B22-B23).

Clinical samples		Results
Serological diagnosis (ELISA)	n	cPCR (B22-B23)		qPCR (REP-529)			qPCR (B1)
		Negative	Positive	Negative	Positive	%	Negative	Positive	%
Negative	122	122	0	121	1	99.2^a	122	0	100^a
Positive	393	247	146^b	253	140	95.9^b	281	122	83.6

Total	515	369	146	374	141	–	403	122	–

Open in a separate window

^aPercent of specificity was calculated as ratio of true negatives/true negatives + false positives × 100 (clinical diagnosis and ELISA results were considered gold standard method − 122 patients without toxoplasmosis).

^bPercent of sensitivity was calculated as ratio of true positives/true positives + false negatives × 100 (clinical diagnosis and cPCR were considered gold standard method).